(Total Views: 341)
Posted On: 12/17/2018 9:17:11 AM
Post# of 72446
I don't believe P was thought to be a long shot by most here:
Higher dose. (300-400mg vs 200mg)
More severe disease. (mod-sev vs mild-mod)
Easier grading index (PASI)
There were many reasons to believe we would match or exceed the 2a data. The one reason to believe we wouldn't was the small patient pool in the 200mg arm.
That is what terrifies me about B-OM subgroups and Kevetrin. The numbers are small and Prurisol is an example of what can happen when your numbers are small.
Thankfully we still have B-ABSSSI in the stable which can probably net us $50M-$100M.
Go IPIX!
Higher dose. (300-400mg vs 200mg)
More severe disease. (mod-sev vs mild-mod)
Easier grading index (PASI)
There were many reasons to believe we would match or exceed the 2a data. The one reason to believe we wouldn't was the small patient pool in the 200mg arm.
That is what terrifies me about B-OM subgroups and Kevetrin. The numbers are small and Prurisol is an example of what can happen when your numbers are small.
Thankfully we still have B-ABSSSI in the stable which can probably net us $50M-$100M.
Go IPIX!
(0)
(1)
